Profile data is unavailable for this security.
About the company
Shanghai Yizhong Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development and industrialization of new and improved anti-tumor drugs. The Company's main products include paclitaxel micelles, docetaxel micelles and cabazitaxel micelles. Paclitaxel micelles are products under development that have been submitted for registration and marketing applications, and their indications are non-small cell lung cancer. Docetaxel micelles and cabazitaxel micelles are products under development in the pre-clinical research stage.
- Revenue in CNY (TTM)247.05m
- Net income in CNY22.96m
- Incorporated2009
- Employees65.00
- LocationShanghai Yizhong Pharmaceutical Co LtdNo. 79 Renqi Road, Fengxian DistrictSHANGHAI 201401ChinaCHN
- Phone+86 2 137190005
- Fax+86 2 137190005
- Websitehttps://www.yizhongpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North China Pharmaceutical Co Ltd | 9.79bn | 183.03m | 9.57bn | 10.09k | 52.40 | 1.74 | -- | 0.9775 | 0.1065 | 0.1065 | 5.69 | 3.21 | 0.453 | 2.91 | 4.26 | 970,873.20 | 1.30 | -0.2469 | 3.23 | -0.578 | 30.05 | 33.78 | 2.86 | -0.5243 | 0.4902 | 2.22 | 0.6254 | -- | -2.48 | -2.94 | 2,496.80 | -5.90 | 3.21 | 0.00 |
| Shandong Lukang Pharmaceutical Co Ltd | 6.19bn | 188.75m | 9.65bn | 6.39k | 44.18 | 2.10 | -- | 1.56 | 0.2089 | 0.2089 | 6.85 | 4.40 | 0.6891 | 3.69 | 6.77 | 969,079.80 | 2.20 | 2.78 | 3.60 | 5.00 | 22.98 | 22.76 | 3.20 | 4.17 | 0.7984 | 6.01 | 0.4324 | 31.07 | 1.41 | 10.80 | 60.30 | 26.62 | -19.55 | 24.01 |
| Chengdu Olymvax Biopharmaceuticals Inc | 709.13m | 64.21m | 9.74bn | 470.00 | 151.22 | 10.15 | -- | 13.73 | 0.1587 | 0.1587 | 1.75 | 2.36 | 0.3883 | 0.654 | 1.19 | 1,508,792.00 | 3.45 | 3.25 | 5.00 | 4.81 | 92.66 | 93.62 | 8.88 | 8.11 | 1.42 | 8.30 | 0.2906 | 7.39 | 18.69 | 26.88 | 18.24 | -- | 48.00 | -- |
| Youcare Pharmaceutical Group Co Ltd | 2.55bn | -233.99m | 9.92bn | 3.28k | -- | 2.89 | -- | 3.89 | -0.5306 | -0.5306 | 5.75 | 7.62 | 0.4537 | 2.18 | 4.03 | 777,123.10 | -4.30 | 5.90 | -5.97 | 8.92 | 47.55 | 63.64 | -9.48 | 7.49 | 1.49 | -41.24 | 0.1633 | 66.99 | -9.90 | -2.48 | -33.05 | -15.40 | 19.36 | -- |
| Chongqing Taiji Industry Group Co Ltd | 10.04bn | -352.52m | 10.02bn | 11.97k | -- | 2.83 | -- | 0.9979 | -0.8238 | -0.8238 | 18.98 | 6.42 | 0.7032 | 2.85 | 3.55 | 838,688.20 | -2.36 | 0.9924 | -6.94 | 3.04 | 26.30 | 43.37 | -3.35 | 1.08 | 0.4906 | 0.5756 | 0.5914 | 22.39 | -20.72 | 1.24 | -96.76 | -- | -3.36 | -- |
| Chongqing Genrix Biophrmctcl Co Ltd | 225.16m | -583.52m | 10.24bn | 743.00 | -- | 5.73 | -- | 45.47 | -1.59 | -1.59 | 0.6141 | 4.88 | 0.0712 | 0.3088 | 10.33 | 303,044.90 | -18.45 | -- | -19.95 | -- | 90.99 | -- | -259.16 | -- | 7.37 | -- | 0.3694 | -- | 2,384.11 | -- | 0.5049 | -- | -- | -- |
| Shanghai Yizhong Pharmaceutical Co Ltd | 247.05m | 22.96m | 10.31bn | 65.00 | 440.89 | 7.06 | -- | 41.75 | 0.1132 | 0.1132 | 1.22 | 7.07 | 0.163 | 0.9556 | 2.26 | 3,800,801.00 | 1.51 | 5.44 | 1.58 | 5.64 | 81.39 | 92.99 | 9.30 | 36.90 | 7.84 | -- | 0.00 | 32.30 | -51.83 | -- | -95.68 | -- | 10.96 | -- |
| Liaoning Chengda Biotechnology Co Ltd | 1.47bn | 177.94m | 10.78bn | 1.81k | 59.79 | 1.15 | -- | 7.34 | 0.433 | 0.433 | 3.56 | 22.54 | 0.1482 | 0.6786 | 1.24 | 813,192.10 | 1.79 | 8.07 | 1.86 | 8.36 | 79.03 | 84.98 | 12.11 | 35.75 | 19.28 | -- | 0.0013 | 44.77 | -4.22 | -0.0082 | -26.42 | -13.26 | -4.72 | -- |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 1.90bn | 498.69m | 11.11bn | 2.03k | 22.03 | 3.57 | -- | 5.85 | 1.60 | 1.60 | 6.13 | 9.84 | 0.3413 | 0.9306 | 3.06 | 936,748.90 | 8.90 | 7.19 | 13.04 | 9.67 | 66.64 | 59.30 | 26.08 | 20.28 | 0.928 | 16.07 | 0.4604 | 35.89 | 57.21 | 34.33 | 148.19 | 52.76 | 31.58 | -- |
Data as of Feb 06 2026. Currency figures normalised to Shanghai Yizhong Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
4.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 3.09m | 1.50% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 1.55m | 0.75% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 1.17m | 0.57% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 742.96k | 0.36% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 616.15k | 0.30% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 541.92k | 0.26% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 245.91k | 0.12% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 186.67k | 0.09% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2025 | 130.85k | 0.06% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 114.62k | 0.06% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
